ClinicalTrials.gg
CompletedNCT05973006COVID-19Updated Jul 15, 2025Results posted

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

A Phase 3 interventional study of NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine and Prototype/XBB.1.5 Bivalent Vaccine (5 µg) in COVID-19, sponsored by Novavax. Completed at 20 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Novavax · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in COVID-19 by Novavax — none open to participants now, none under way, none of them phase 3. COVID-19 · Novavax.

Enrollment
15th of 21
400 · median 911
Started
2023
with 3 others
Phase 3
8 of 21
none open now
Registered
15th of 21
by date

Among the 21 studies in COVID-19 by Novavax, this one is the 15th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 3, and was the 15th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 21 studies in COVID-19 by Novavax is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in COVID-19 by Novavax as a file.
02

Study summary

This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5. The main focus is on safety: researchers want to see if this new booster is safe for teenagers who have already received two doses of the Pfizer or Moderna mRNA COVID-19 vaccines. To ensure a fair comparison, the study will use a double-blind approach. This means two groups of teenagers will receive booster shots, but neither the teenagers nor the researchers giving the shots will know beforehand which version of the booster each person gets. The study will also assess how well the body fights the virus after the booster shot.

Read the detailed description

This is a Phase 3, randomized, double-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccines (SARS-CoV-2 rS) adjuvanted with Matrix-M™ adjuvant (NVX-CoV2601 [Omicron XBB.1.5]) and bivalent (NVX-CoV2373 [prototype] + NVX CoV2601) in previously vaccinated adolescent participants ≥ 12 to \< 18 years of age.

Approximately 400 adolescents who have received a regimen of ≥ 2 doses of the Moderna and/or Pfizer-BioNTech monovalent and/or bivalent COVID-19 vaccines ≥ 90 days previously will be randomized 1:1 to Group A or Group B:

  • Group A: 1 dose of NVX-CoV2601 (1 on Day 0)
  • Group B: 1 dose of bivalent NVX-CoV2373 + NVX-CoV2601 (1 on Day 0) All participants will remain on study for immunogenicity and safety data collection through Day 180.
03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adolescents ≥ 12 to \< 18 years of age at screening
  2. Participant and parent(s)/caregiver(s) or legally acceptable representative willing and able to give in-formed consent and assent, as required, prior to study enrollment and to comply with study procedures.
  3. Participants of (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea ≥ 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of the study OR agree to consistently use a medically acceptable method of listed below from ≥ 28 days prior to enrollment and through the end of the study.
  4. Is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the vaccination.
  5. Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study.
  6. Have previously received ≥ 2 doses of the Moderna and/or Pfizer-BioNTech monovalent and/or bivalent COVID-19 vaccines with the last dose having been given ≥ 90 days previously prior to study vaccination.

Exclusion criteria

Exclusion Criteria:

  1. Received COVID-19 vaccines other than Moderna and/or Pfizer-BioNTech in the past, inclusive of clinical trial COVID-19 vaccines.
  2. Participation in research involving receipt of products (drug/biologic/device) within 90 days prior to study vaccination.
  3. Received influenza vaccination within 14 days prior to study vaccination.
  4. Received any vaccine ≤ 45 days prior to study vaccination, except for rabies, human papilloma virus (HPV), tetanus-diphtheria (Td), tetanus, diphtheria, and pertussis (TDaP/DTap), virus (HBV), and meningococcal vaccines which may be given as medically indicated.
  5. Any known allergies to products contained in the investigational product.
  6. Any history of anaphylaxis to any prior vaccine.
  7. or immunodeficiency disease/condition (iatrogenic or congenital) requiring ongoing immunomodulatory therapy.
  8. Chronic administration (defined as > 14 continuous days) of , systemic , or other immune-modifying drugs within 90 days prior to study vaccination.

    An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical or intranasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted.

  9. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination, except for rabies immunoglobulin which may be given if medically indicated.
  10. Active cancer () on therapy within 3 years prior to study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
  11. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of study.
  12. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
  13. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
  14. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization [CRO], and study site personnel involved in the conduct or planning of the study).
  15. Participants with a history of myocarditis or pericarditis.
  16. Respiratory symptoms in the past 3 days (ie, cough, sore throat, difficulty breathing).
  17. Temperature of > 38°C within 24 hours of planned study vaccination (site measured or participant measured).
  18. Blood pressure of ≥ 160/100 mmHg.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Group-A NVX-CoV2601

    The Monovalent NVX-CoV2601 of 5 μg of antigen with 50 μg of Matrix-M adjuvant

    Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine

  • Active comparator
    Group-B Bivalent NVX CoV2373 + NVX CoV2601

    The Bivalent NVX CoV2373 + NVX CoV2601 of 5 μg of each antigen with a total of 50 μg of Matrix-M adjuvant

    Biological: Prototype/XBB.1.5 Bivalent Vaccine (5 µg)

Interventions

  • BiologicalNVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine

    Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.

    Also known as: NVX-CoV2601

  • BiologicalPrototype/XBB.1.5 Bivalent Vaccine (5 µg)

    A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.

    Also known as: Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant

06

What researchers measure

Primary outcomes

  1. Participants With Solicited Local and Systemic AEs for 7 Days Following Vaccination

    Participants with solicited local and systemic adverse events (AEs) To assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) for 7 days following vaccination

    Time frame: Day 7

  2. Participants With Unsolicited AEs Through 28 Days After Vaccination

    Participants with unsolicited AEs to assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) through 28 days after vaccination.

    Time frame: Day 28

  3. Participants With (MAAEs) Attributed to Study Vaccine, (AESIs) (PIMMCs), Myocarditis and/or Pericarditis, and Complications Specific to COVID-19), and Serious Adverse Events (SAEs)

    Participants with medically attended adverse events (MAAEs) attributed to study vaccine, adverse events of special interest (AESIs) (predefined list including potential immune-mediated medical conditions (PIMMCs), myocarditis and/or pericarditis, and complications specific to COVID-19), and serious adverse events (SAEs) o assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601)through day 180 or end of study (EOS).

    Time frame: Day 180

  4. Immunogenicity Index- Neutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.

    The neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain assessed at Day 28 following initial study vaccination.

    Time frame: Day 0 and Day 28

  5. Immunogenicity Index- The Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.

    the neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain, assessed at Day 28

    Time frame: Day 28

Secondary outcomes

  1. Neutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.

    the neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.

    Time frame: Day 0 to Day 180

  2. Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.

    The neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.

    Time frame: Day 28 to Day 180

  3. IgG Geometric Mean ELISA (Enzyme-linked Immunosorbent Assay) Units (GMEUs) to the Omicron XBB.1.5 S Protein.

    The immunoglobulin G (IgG) antibody levels induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time.at relevant time points.

    Time frame: Day 0 to Day 180

  4. NAb(Neutralizing Antibody Titers) Levels Are Measured to the Ancestral (Wuhan) Strain .

    The NAb antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points .

    Time frame: Day 0 to 180

  5. Serum IgG GMEUs Levels Are Measured to the Ancestral (Wuhan) Strain .

    The serum IgG antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points.

    Time frame: Day 0 to Day 180

07

Results

Posted Jul 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Started190210
Completed187201
Not completed39
Withdrew: Early termination39

Outcome measures

PrimaryParticipants With Solicited Local and Systemic AEs for 7 Days Following Vaccination

Participants with solicited local and systemic adverse events (AEs) To assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) for 7 days following vaccination

Time frame:
Day 7
Reported as:
Number · participants
Participants With Solicited Local and Systemic AEs for 7 Days Following Vaccination
participantsGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Any Solicited AEs153166
Local AEs136140
Systemic AEs116120
PrimaryParticipants With Unsolicited AEs Through 28 Days After Vaccination

Participants with unsolicited AEs to assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) through 28 days after vaccination.

Time frame:
Day 28
Reported as:
Number · participants
Participants With Unsolicited AEs Through 28 Days After Vaccination
participantsGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Any unsolicited TEAE through 28 days after study vaccination2525
Infections and infestations1513
Psychiatric disorders42
General disorders and administration site conditions33
Respiratory, thoracic and mediastinal disorders23
Gastrointestinal disorders31
Skin and subcutaneous tissue disorders21
Injury, poisoning and procedural complications20
Blood and lymphatic system disorders11
Musculoskeletal and connective tissue disorders11
Nervous system disorders01
Metabolism and nutrition disorders01
PrimaryParticipants With (MAAEs) Attributed to Study Vaccine, (AESIs) (PIMMCs), Myocarditis and/or Pericarditis, and Complications Specific to COVID-19), and Serious Adverse Events (SAEs)

Participants with medically attended adverse events (MAAEs) attributed to study vaccine, adverse events of special interest (AESIs) (predefined list including potential immune-mediated medical conditions (PIMMCs), myocarditis and/or pericarditis, and complications specific to COVID-19), and serious adverse events (SAEs) o assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601)through day 180 or end of study (EOS).

Time frame:
Day 180
Reported as:
Number · participants
Participants With (MAAEs) Attributed to Study Vaccine, (AESIs) (PIMMCs), Myocarditis and/or Pericarditis, and Complications Specific to COVID-19), and Serious Adverse Events (SAEs)
participantsGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Any TEAEs2525
Any MAAEs1612
Any Serious TEAEs41
PrimaryImmunogenicity Index- Neutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.

The neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain assessed at Day 28 following initial study vaccination.

Time frame:
Day 0 and Day 28
Reported as:
Geometric mean · geometric mean titer
Immunogenicity Index- Neutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.
geometric mean titerGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Day 0208.40 (166.20 to 261.32)184.81 (148.86 to 229.45)
Day 282533.08 (2107.17 to 3045.07)1544.61 (1314.33 to 1815.25)
PrimaryImmunogenicity Index- The Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.

the neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain, assessed at Day 28

Time frame:
Day 28
Reported as:
Geometric mean · geometric mean fold rise
Immunogenicity Index- The Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.
geometric mean fold riseGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Immunogenicity Index- The Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.12.2 (9.5 to 15.5)8.4 (6.8 to 10.3)
SecondaryNeutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.

the neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.

Time frame:
Day 0 to Day 180
Reported as:
Geometric mean · geometric mean titer
Neutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.
geometric mean titerGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Day 0204.98 (163.68 to 256.69)183.37 (147.82 to 227.47)
Day 282533.08 (2107.17 to 3045.07)1544.61 (1314.33 to 1815.25)
Day 901816.50 (1505.62 to 2191.56)1171.90 (997.69 to 1376.52)
Day 1801369.61 (1128.29 to 1662.53)866.10 (733.49 to 1022.67)
SecondaryNeutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.

The neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.

Time frame:
Day 28 to Day 180
Reported as:
Geometric mean · geometric mean fold rise
Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.
geometric mean fold riseGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Day 2812.2 (9.5 to 15.5)8.4 (6.8 to 10.3)
Day 908.6 (6.7 to 11.1)6.2 (5.0 to 7.7)
Day 1806.0 (4.7 to 7.8)4.7 (3.7 to 5.9)
SecondaryIgG Geometric Mean ELISA (Enzyme-linked Immunosorbent Assay) Units (GMEUs) to the Omicron XBB.1.5 S Protein.

The immunoglobulin G (IgG) antibody levels induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time.at relevant time points.

Time frame:
Day 0 to Day 180
Reported as:
Geometric mean · Elisa Units per mL
IgG Geometric Mean ELISA (Enzyme-linked Immunosorbent Assay) Units (GMEUs) to the Omicron XBB.1.5 S Protein.
Elisa Units per mLGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Day 038825.1 (33160.1 to 45457.9)32881.9 (28434.7 to 38024.7)
Day 28150232.9 (132853.6 to 169885.6)113031.9 (101227.0 to 126213.4)
Day 90110091.1 (96294.7 to 125864.3)87102.4 (77115.6 to 98382.6)
Day 18077149.8 (68110.5 to 87388.8)61647.7 (55459.2 to 68526.7)
SecondaryNAb(Neutralizing Antibody Titers) Levels Are Measured to the Ancestral (Wuhan) Strain .

The NAb antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points .

Time frame:
Day 0 to 180
Reported as:
Geometric mean · geometric mean titer
NAb(Neutralizing Antibody Titers) Levels Are Measured to the Ancestral (Wuhan) Strain .
geometric mean titerGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Day 01321.00 (1123.04 to 1553.87)1197.59 (1029.90 to 1392.58)
Day 283510.84 (3099.99 to 3976.14)2803.80 (2453.96 to 3203.51)
Day 903381.08 (2991.33 to 3821.62)2924.82 (2581.96 to 3313.23)
Day 1802663.87 (2334.49 to 3039.72)2357.51 (2095.11 to 2652.77)
SecondarySerum IgG GMEUs Levels Are Measured to the Ancestral (Wuhan) Strain .

The serum IgG antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points.

Time frame:
Day 0 to Day 180
Reported as:
Geometric mean · Elisa Units per mL
Serum IgG GMEUs Levels Are Measured to the Ancestral (Wuhan) Strain .
Elisa Units per mLGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Day 071388.4 (62262.8 to 81851.6)61296.9 (53962.1 to 69628.5)
Day 28181736.6 (162092.7 to 203761.1)157077.8 (141109.2 to 174853.4)
Day 90142032.4 (124824.9 to 161611.9)130155.1 (116798.0 to 145039.8)
Day 180104890.2 (93135.9 to 118128.0)94026.0 (84606.1 to 104494.8)

Adverse events

Collected over 180 Days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group-A NVX-CoV26010/190 (0%)7/190 (3.7%)10/190 (5.3%)
Group-B Bivalent NVX CoV2373 + NVX CoV26010/210 (0%)1/210 (0.5%)4/210 (1.9%)
Most frequent serious events
Most frequent serious events
EventGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Suicidal ideationPsychiatric disorders3/1900/210
Adjustment disorder with anxietyPsychiatric disorders1/1900/210
Adjustment disorder with depressed moodPsychiatric disorders1/1900/210
DepressionPsychiatric disorders1/1900/210
Post-traumatic stress disorderPsychiatric disorders1/1900/210
Disruptive mood dysregulation disorderPsychiatric disorders0/1901/210
Most frequent other events
Most frequent other events
EventGroup-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601
Upper respiratory tract infectionInfections and infestations10/1904/210

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601Total
Mean14.5 ± 1.7714.5 ± 1.6514.5 ± 1.05
Sex: Female, Male
Sex: Female, Male(Participants)Group-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601Total
Female99107206
Male91103194
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601Total
Hispanic or Latino434790
Not Hispanic or Latino147163310
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group-A NVX-CoV2601Group-B Bivalent NVX CoV2373 + NVX CoV2601Total
American Indian or Alaska Native000
Asian8210
Native Hawaiian or Other Pacific Islander112
Black or African American334477
White137149286
More than one race91019
Unknown or Not Reported246
08

Study locations

20 sites
  • Alfa Medical Research
    Davie, Florida 33024, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • ITB Research
    Miami, Florida 33173, United States
  • Velocity Clinical Research
    Meridian, Idaho 83642, United States
  • DM Clinical Research - Chicago
    River Forest, Illinois 60305, United States
  • Johnson County Clinical Trials
    Lenexa, Kansas 66219, United States
  • Alliance for Multispecialty Research, LLC (AMR)
    Newton, Kansas 67114, United States
  • AMR
    Wichita, Kansas 67207, United States
  • Velocity Clinical Research
    Lafayette, Louisiana 70508, United States
  • Velocity Clinical Research
    Vestal, New York 13850, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45246, United States
  • Tekton Research
    Tulsa, Oklahoma 74137, United States
  • Clinical Research Associates, Inc
    Nashville, Tennessee 37203, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • South Texas Clinical Research
    Corpus Christi, Texas 78404, United States
  • DM Clinical Research
    Houston, Texas 77065, United States
  • Medical Colleagues of Texas, LLP
    Katy, Texas 77450, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Tekton Research
    San Antonio, Texas 78244, United States
  • Mountain View CCT Research
    Pleasant View, Utah 84404, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2024, 7 months.

Results were first posted in Jul 2025, 1 year 3 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 2, 2023
StartActual
Aug 16, 2023
Primary completionActual
Apr 1, 2024
CompletionActual
Sep 30, 2024
Results first posted
Jul 15, 2025
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05973006
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Aug 16, 2023
Primary completion
Apr 1, 2024
Completion
Sep 30, 2024
Results posted
Jul 15, 2025
Last update
Jul 15, 2025

Study contacts

Clinical Development
study director · Novavax

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion